Biogen

Key TakeawaysLEQEMBI’s approval addresses a critical need in Mexico, where Alzheimer’s accounts for the majority of dementia cases. The drug’s ability to reduce...

Biogen Japan has announced a groundbreaking research initiative focused on the APOE gene, a critical factor in Alzheimer's disease (AD) progression. Spearheaded by CEO...

Key TakeawaysDZP achieved a 14.6% higher BICLA response rate at 48 weeks compared to SOC alone. Participants on DZP experienced a 50% reduction...

Key TakeawaysHealthcare providers can incorporate OPUVIZ as a reliable and cost-effective alternative to Eylea, expanding treatment options for patients. Patients may benefit from...

Key TakeawaysLEQEMBI's subcutaneous delivery method could reduce hospital visits and enhance patient adherence. The autoinjector targets early Alzheimer's stages, aiming to prolong therapeutic...

Key TakeawaysFelzartamab reduced proteinuria significantly, showing approximately a 50% reduction persisting 18 months after the last dose. Kidney function remained stable throughout the...

Key TakeawaysEisai and Biogen have announced plans to appeal the Therapeutic Goods Administration's (TGA) initial decision to deny registration for lecanemab in Australia,...

Key TakeawaysAustralia's Therapeutic Goods Administration (TGA) has temporarily denied approval for lecanemab, Eisai and Biogen's monoclonal antibody for early-stage Alzheimer's disease. Eisai and...

Key TakeawaysFelzartamab, Biogen’s investigational anti-CD38 monoclonal antibody, gains FDA Breakthrough Therapy Designation for treating antibody-mediated rejection (AMR) in kidney transplant patients. Clinical data...

Key TakeawaysHigher dose nusinersen shows improved efficacy and safety in patients with spinal muscular atrophy (SMA), both treatment-naïve and previously treated, per new...

Key TakeawaysThe G-BA's assessment of Tofersen highlights significant survival and quality of life improvements for amyotrophic lateral sclerosis patients with SOD1 mutations, particularly...

Key TakeawaysDapirolizumab pegol demonstrated clinical improvement in moderate-to-severe SLE patients. The drug also showed positive outcomes in reducing disease activity and flares. No...

Key TakeawaysOPUVIZ™, a biosimilar referencing aflibercept (Eylea), has received a positive recommendation from the EMA's CHMP for the treatment of several retinal disorders. ...

Key TakeawaysBiogen's Phase 2/3 DEVOTE study demonstrated that a higher dose regimen of nusinersen significantly improves motor function in infants with spinal muscular...

Alzheimer’s disease (AD) has taken another significant step forward in treatment, with the authorization of Leqembi® (lecanemab) in Great Britain for the treatment of...